Clinical Trial RESULTS
Clinical Trial
RESULTS
Research Sponsor: AstraZeneca AB
Drug Studied: AZD9291 (osimertinib)
National Clinical Trial #: NCT02491944
Eudra CT #: 2015-000448-41
Protocol #: D5160C00020
Study Date: July 2015 to August 2015
Short Study Title: A study in healthy males to see how much
of osimertinib is taken up by the body when
taken by mouth compared with an injection
into the vein
Thank you!
As a clinical study participant, you belong to a large community of
participants around the world. You help researchers answer important
health questions and discover new medical treatments.
Thank you for taking part in the clinical study for the study drug
osimertinib, a newly approved drug being developed to treat lung
cancer. You and all of the participants helped researchers learn how
osimertinib is affected by the body.
AstraZeneca AB, the sponsor of this study, thanks you for your help
and thinks it is important for you to know the results of your study.
An independent non-profit organisation called CISCRP prepared this
summary of the study results for you with the help of a medical writing
organisation. We hope it helps you understand and feel proud of your
important role in medical research. If you have questions about the
results, please speak with the doctor or staff at your study site.
11